Quarterly report pursuant to Section 13 or 15(d)

Non-Controlling Interests (Details)

v3.19.2
Non-Controlling Interests (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Dec. 31, 2018
Noncontrolling Interest [Line Items]          
NCI equity share     $ 89,975   $ 75,680
Net loss attributable to non-controlling interest $ (14,382) $ (14,105) (32,029) $ (31,305) (57,789)
Non-controlling interests in consolidated entities 57,946   57,946   17,891
Aevitas [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share     (1,169)   (474)
Net loss attributable to non-controlling interest     (301)   (606)
Non-controlling interests in consolidated entities $ (1,470)   $ (1,470)   $ (1,080)
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners 36.10%   36.10%   36.10%
Avenue [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share [1]     $ 23,900   $ 13,326
Net loss attributable to non-controlling interest [1]     (13,172)   (13,735)
Non-controlling interests in consolidated entities [1] $ 10,728   $ 10,728   $ (409)
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners [1] 77.20%   77.20%   64.80%
Caelum [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share         $ (2,436)
Net loss attributable to non-controlling interest         (2,413)
Non-controlling interests in consolidated entities         $ (4,849)
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners         36.80%
Cellvation [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share     $ (697)   $ (457)
Net loss attributable to non-controlling interest     (90)   (185)
Non-controlling interests in consolidated entities $ (787)   $ (787)   $ (642)
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners 21.10%   21.10%   21.10%
Checkpoint Therapeutics, Inc [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share [2]     $ 12,042   $ 31,648
Net loss attributable to non-controlling interest [2]     (7,069)   (23,470)
Non-controlling interests in consolidated entities [2] $ 4,973   $ 4,973   $ 8,178
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners [2] 69.00%   69.00%   69.30%
Coronado SO [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share     $ (290)   $ (290)
Net loss attributable to non-controlling interest         0
Non-controlling interests in consolidated entities $ (290)   $ (290)   $ (290)
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners 13.00%   13.00%   13.00%
Cyprium [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share     $ (292)   $ (210)
Net loss attributable to non-controlling interest     (73)   (62)
Non-controlling interests in consolidated entities $ (365)   $ (365)   $ (272)
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners 10.60%   10.60%   10.80%
Helocyte [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share     $ (4,136)   $ (3,372)
Net loss attributable to non-controlling interest     (79)   (684)
Non-controlling interests in consolidated entities $ (4,215)   $ (4,215)   $ (4,056)
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners 19.30%   19.30%   19.80%
JMC [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share     $ (223)   $ (475)
Net loss attributable to non-controlling interest     83   245
Non-controlling interests in consolidated entities $ (140)   $ (140)   $ (230)
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners 6.90%   6.90%   6.90%
Mustang Therapeutics, Inc [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share [1]     $ 61,361   $ 38,631
Net loss attributable to non-controlling interest [1]     (11,263)   (16,628)
Non-controlling interests in consolidated entities [1] $ 50,098   $ 50,098   $ 22,003
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners [1] 70.10%   70.10%   60.50%
Tamid [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share     $ (521)   $ (211)
Net loss attributable to non-controlling interest     (65)   (251)
Non-controlling interests in consolidated entities $ (586)   $ (586)   $ (462)
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners 23.40%   23.40%   23.40%
[1] Avenue and Mustang are consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Preferred Class A Shares which provide super-majority voting rights.
[2] Checkpoint is consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A Common Shares which provide super-majority voting rights.